Investigational drug · Phase 3
IBI306
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
11
Any phase or sponsor naming "IBI306"
First trial start
2026
Apr 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI306", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI306" as an intervention, largest first.
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial HypercholesterolemiaPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04289285 · 804 participants · Start Apr 29, 2020 · Primary completion Feb 9, 2022
Drug: IBI306 450mg SC Q4W; Placebo SC Q4W and 1 more · For: Hypercholesterolemia
Sites: Beijing, China
- A Study of IBI306 in Participants With HypercholesterolemiaPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04709536 · 306 participants · Start Feb 9, 2021 · Primary completion Nov 9, 2021
Drug: IBI306; Placebo · For: Hypercholesterolemia
Sites: Beijing, China
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07473960 · 198 participants · Start Apr 1, 2026 · Primary completion Aug 26, 2026
Drug: IBI306; placebo and 2 more · For: Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Sites: Beijing, China
- Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male VolunteersPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05792917 · 166 participants · Start Mar 6, 2023 · Primary completion Mar 26, 2023
Drug: tafolecimab (a modified manufacturing process); tafolecimab (a original manufacturing process) · For: Healthy Male Subjects
Sites: Beijing, China
- Safety and Efficacy of IBI306 in HeFH PatientsPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04179669 · 149 participants · Start Dec 20, 2019 · Primary completion Jun 30, 2021
Drug: IBI306; placebo · For: Heterozygous Familial Hypercholesterolemia
Sites: Beijing, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT07717242 · 80 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 30, 2028
Drug: Disitamab vedotin; Toripalimab and 4 more · For: Bladder Urothelial Carcinoma; Bladder Cancer
Sites: Guangzhou, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT03815812 · 60 participants · Start Mar 7, 2019 · Primary completion Dec 25, 2019
Drug: IBI306; placebo · For: Hypercholesterolemia
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT03366688 · 58 participants · Start Nov 27, 2017 · Primary completion Nov 5, 2018
Drug: IBI306; placebo · For: Hypercholesterolemia
Sites: Beijing, China
- Application of PCSK9 Inhibitors in Patients With Heterozygous Familial HypercholesterolemiaPivotal-lookingStatus unknown
Shenzhen People's HospitalAcademic, hospital or other
NCT04759534 · 20 participants · Start Sep 10, 2020 · Primary completion Oct 30, 2021
Drug: protein convertase subtilisin/kexin type 9 inhibitor · For: Efficacy and Safety; Heterozygous Familial Hypercholesterolemia; PCSK9
Sites: Shenzhen, China
- A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial HypercholesterolemiaPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04031742 · 18 participants · Start Sep 29, 2019 · Primary completion Dec 30, 2021
Drug: IBI306; IBI306 · For: Homozygous Familial Hypercholesterolemia
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.
Qi L, Liu D, Qu Y, et al. · JACC Asia 2023
- A Potential Long-Acting LDL-Cholesterol-Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies.
Cui Y, Zhao X, Qi L, et al. · JACC Asia 2021
Also in development for Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
- SYH2053Phase 34 trials
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Non-familial Hypercholesterolemia and Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), Hypercholesterolemia and Mixed Hyperlipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.